Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan · Delayed Price · Currency is TWD 31.75
+0.15 (0.47%)
At close: Feb 11, 2026
Advagene Biopharma Market Cap
Advagene Biopharma has a market cap or net worth of 1.89 billion as of February 11, 2026. Its market cap has increased by 54.50% in one year.
Market Cap
1.89B
Enterprise Value
1.72B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
31.75
Market Cap Chart
Since November 29, 2018, Advagene Biopharma's market cap has increased from 1.16B to 1.89B, an increase of 62.70%. That is a compound annual growth rate of 6.99%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 10, 2026 | 1.88B | 12.66% |
| Dec 31, 2025 | 1.67B | 36.50% |
| Dec 31, 2024 | 1.22B | -9.95% |
| Dec 29, 2023 | 1.36B | -8.36% |
| Dec 30, 2022 | 1.48B | -38.27% |
| Dec 30, 2021 | 2.40B | 63.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 25, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Sunny Pharmtech | 2.40B |
| Anti-Microbial Savior BioteQ | 2.33B |
| TWi Biotechnology | 2.32B |
| TaiRx | 2.32B |
| Gwo Xi Stem Cell Applied Technology Co. , | 2.30B |
| Chunghwa Chemical Synthesis & Biotech | 1.98B |
| Genomics BioSci & Tech. | 1.81B |
| NeoCore Technology | 1.55B |